These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 32818917)

  • 1. Self-reported review of the value of esketamine in patients with treatment-resistant depression: Understanding the patient experience in the STRIVE Study.
    Starr HL; Abell J; Larish A; Lewis S; DeMuro C; Gogate J; Jamieson C; Daly E; Zaki N; Kramer M
    Psychiatry Res; 2020 Nov; 293():113376. PubMed ID: 32818917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of esketamine nasal spray on depressive symptom severity in adults with treatment-resistant depression and associations between the Montgomery-Åsberg Depression Rating Scale and the 9-item Patient Health Questionnaire.
    Kern Sliwa J; Naranjo RR; Turkoz I; Petrillo MP; Cabrera P; Trivedi M
    CNS Spectr; 2024 Jun; 29(3):176-186. PubMed ID: 38557430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).
    Wajs E; Aluisio L; Holder R; Daly EJ; Lane R; Lim P; George JE; Morrison RL; Sanacora G; Young AH; Kasper S; Sulaiman AH; Li CT; Paik JW; Manji H; Hough D; Grunfeld J; Jeon HJ; Wilkinson ST; Drevets WC; Singh JB
    J Clin Psychiatry; 2020 Apr; 81(3):. PubMed ID: 32316080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data.
    d'Andrea G; Pettorruso M; Di Lorenzo G; Rhee TG; Chiappini S; Carullo R; Barlati S; Zanardi R; Rosso G; Di Nicola M; Andriola I; Marcatili M; Clerici M; Dell'Osso BM; Sensi SL; Mansur RB; Rosenblat JD; Martinotti G; McIntyre RS
    J Affect Disord; 2024 Mar; 348():314-322. PubMed ID: 38145840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study.
    Chiappini S; d'Andrea G; De Filippis S; Di Nicola M; Andriola I; Bassetti R; Barlati S; Pettorruso M; Sensi S; Clerici M; Dell'Osso B; Vita A; Martinotti G
    Eur Neuropsychopharmacol; 2023 Sep; 74():15-21. PubMed ID: 37148637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study.
    Castro M; Wilkinson ST; Al Jurdi RK; Petrillo MP; Zaki N; Borentain S; Fu DJ; Turkoz I; Sun L; Brown B; Cabrera P
    CNS Drugs; 2023 Aug; 37(8):715-723. PubMed ID: 37558912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Response With Esketamine Nasal Spray Plus an Oral Antidepressant in Patients With Treatment-Resistant Depression Without Evidence of Early Response: A Pooled Post Hoc Analysis of the TRANSFORM Studies.
    Turkoz I; Daly E; Singh J; Lin X; Tymofyeyev Y; Williamson D; Salvadore G; Nash AI; Macaluso M; Wilkinson ST; Nelson JC
    J Clin Psychiatry; 2021 Jul; 82(4):. PubMed ID: 34288609
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-Term Efficacy of Intranasal Esketamine in Treatment-Resistant Major Depression: A Systematic Review.
    Capuzzi E; Caldiroli A; Capellazzi M; Tagliabue I; Marcatili M; Colmegna F; Clerici M; Buoli M; Dakanalis A
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
    Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
    Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant.
    Jamieson C; Popova V; Daly E; Cooper K; Drevets WC; Rozjabek HM; Singh J
    Health Qual Life Outcomes; 2023 May; 21(1):40. PubMed ID: 37158911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ; Trivedi MH; Janik A; Li H; Zhang Y; Li X; Lane R; Lim P; Duca AR; Hough D; Thase ME; Zajecka J; Winokur A; Divacka I; Fagiolini A; Cubala WJ; Bitter I; Blier P; Shelton RC; Molero P; Manji H; Drevets WC; Singh JB
    JAMA Psychiatry; 2019 Sep; 76(9):893-903. PubMed ID: 31166571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
    Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB
    Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment patterns, healthcare utilization, and costs of patients with treatment-resistant depression initiated on esketamine intranasal spray and covered by US commercial health plans.
    Joshi K; Pilon D; Shah A; Holiday C; Karkare S; Zhdanava M
    J Med Econ; 2023; 26(1):422-429. PubMed ID: 36924214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression.
    Chen G; Chen L; Zhang Y; Li X; Lane R; Lim P; Daly EJ; Furey ML; Fedgchin M; Popova V; Singh JB; Drevets WC
    Int J Neuropsychopharmacol; 2022 Apr; 25(4):269-279. PubMed ID: 35022754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigating the Effectiveness and Tolerability of Intranasal Esketamine Among Older Adults With Treatment-Resistant Depression (TRD): A Post-hoc Analysis from the REAL-ESK Study Group.
    d'Andrea G; Chiappini S; McIntyre RS; Stefanelli G; Carullo R; Andriola I; Zanardi R; Martiadis V; Sensi SL; Sani G; Clerici M; Di Lorenzo G; Vita A; Pettorruso M; Martinotti G
    Am J Geriatr Psychiatry; 2023 Dec; 31(12):1032-1041. PubMed ID: 37479669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring Esketamine's Therapeutic Outcomes as an FDA-Designated Breakthrough for Treatment-Resistant Depression and Major Depressive Disorder With Suicidal Intent: A Narrative Review.
    Kumari S; Chaudhry HA; Sagot A; Doumas S; Abdullah H; Alcera E; Solhkhah R; Afzal S
    Cureus; 2024 Feb; 16(2):e53987. PubMed ID: 38476783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING).
    Pettorruso M; Guidotti R; d'Andrea G; De Risio L; D'Andrea A; Chiappini S; Carullo R; Barlati S; Zanardi R; Rosso G; De Filippis S; Di Nicola M; Andriola I; Marcatili M; Nicolò G; Martiadis V; Bassetti R; Nucifora D; De Fazio P; Rosenblat JD; Clerici M; Maria Dell'Osso B; Vita A; Marzetti L; Sensi SL; Di Lorenzo G; McIntyre RS; Martinotti G;
    Psychiatry Res; 2023 Sep; 327():115378. PubMed ID: 37574600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3.
    Ochs-Ross R; Daly EJ; Zhang Y; Lane R; Lim P; Morrison RL; Hough D; Manji H; Drevets WC; Sanacora G; Steffens DC; Adler C; McShane R; Gaillard R; Wilkinson ST; Singh JB
    Am J Geriatr Psychiatry; 2020 Feb; 28(2):121-141. PubMed ID: 31734084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study.
    Ochs-Ross R; Wajs E; Daly EJ; Zhang Y; Lane R; Lim P; Drevets WC; Steffens DC; Sanacora G; Jamieson C; Hough D; Manji H; Singh JB
    Am J Geriatr Psychiatry; 2022 May; 30(5):541-556. PubMed ID: 34750057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Esketamine: A Novel Option for Treatment-Resistant Depression.
    Bozymski KM; Crouse EL; Titus-Lay EN; Ott CA; Nofziger JL; Kirkwood CK
    Ann Pharmacother; 2020 Jun; 54(6):567-576. PubMed ID: 31795735
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.